Detail Information of Exogenous Modulation

General Information of Drug Transporter (DT)
DT ID DTD0151 Transporter Info
Gene Name SLC22A4
Transporter Name Organic cation/carnitine transporter 1
Gene ID
6583
UniProt ID
Q9H015
Exogenous factors (drugs, dietary constituents, etc.) Modulation of This DT (EGM)

Approved Drug

  Pyrilamide

            2 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Pyrilamide inhibits the transportation of Ergothioneine by SLC22A4 (Ki = 182 microM) [1]

Affected Drug/Substrate

 Ergothioneine Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-OCTN1

  DT Modulation 2

 Pyrilamide inhibits the transportation of Tetraethylammonium by SLC22A4 [2]

Affected Drug/Substrate

 Tetraethylammonium Modulation Type Inhibition

Cell System

 Oocytes-OCTN1

  Quinine

            2 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Quinine inhibits the transportation of Tetraethylammonium by SLC22A4 (IC50 < 1000 microM) [2]

Affected Drug/Substrate

 Tetraethylammonium Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-OCTN1

  DT Modulation 2

 Quinine inhibits the transportation of Ergothioneine by SLC22A4 [3]

Affected Drug/Substrate

 Ergothioneine Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-OCTN1

  Methimazole

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Methimazole inhibits the transportation of Ergothioneine by SLC22A4 (Ki = 7520 microM) [1]

Affected Drug/Substrate

 Ergothioneine Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-OCTN1

  Verapamil

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Verapamil inhibits the transportation of Ergothioneine by SLC22A4 (Ki = 10.8 microM) [1]

Affected Drug/Substrate

 Ergothioneine Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-OCTN1

  Procainamide

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Procainamide inhibits the transportation of Tetraethylammonium by SLC22A4 (IC50 < 1000 microM) [2]

Affected Drug/Substrate

 Tetraethylammonium Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-OCTN1

  Linagliptin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Linagliptin inhibits the transportation of Ergothioneine by SLC22A4 [3]

Affected Drug/Substrate

 Ergothioneine Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-OCTN1

  L-carnitine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 L-carnitine inhibits the transportation of Tetraethylammonium by SLC22A4 [2]

Affected Drug/Substrate

 Tetraethylammonium Modulation Type Inhibition

Cell System

 Oocytes-OCTN1

  Nicotine polacrilex

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Nicotine inhibits the transportation of Tetraethylammonium by SLC22A4 [2]

Affected Drug/Substrate

 Tetraethylammonium Modulation Type Inhibition

Cell System

 Oocytes-OCTN1

  Ofloxacin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Ofloxacin inhibits the transportation of Tetraethylammonium by SLC22A4 [2]

Affected Drug/Substrate

 Tetraethylammonium Modulation Type Inhibition

Cell System

 Oocytes-OCTN1

  Troglitazone

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Troglitazone increases the expression of SLC22A4 [4]

  Cyclosporine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Cyclosporine increases the expression of SLC22A4 [5]

  Zidovudine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Zidovudine increases the expression of SLC22A4 [6]

  Zoledronic Acid

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Zoledronic Acid increases the expression of SLC22A4 [7]

  Acetaminophen

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Acetaminophen inhibits the expression of SLC22A4 [8]

  Decitabine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Decitabine increases the expression of SLC22A4 [9]

  Leflunomide

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Leflunomide inhibits the expression of SLC22A4 [10]

  Doxorubicin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Doxorubicin inhibits the expression of SLC22A4 [11]

  Estradiol

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Estradiol increases the expression of SLC22A4 [12]

  Valproic Acid

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Valproic Acid increases the expression of SLC22A4 [13]

  Tretinoin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Tretinoin increases the expression of SLC22A4 [14]

  Cimetidine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Cimetidine inhibits the activity of SLC22A4 [15]

Drug in Phase 2 Trial

  Bisphenol A

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Bisphenol A increases the expression of SLC22A4 [23]

Discontinued Drug

  Thioperamide

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Thioperamide inhibits the transportation of Ergothioneine by SLC22A4 (Ki = 254 microM) [1]

Affected Drug/Substrate

 Ergothioneine Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-OCTN1

Natural Product

  Particulate Matter

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Particulate Matter increases the expression of SLC22A4 [22]

  Tobacco Smoke Pollution

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Tobacco Smoke Pollution inhibits the expression of SLC22A4 [26]

Environmental toxicant

  Polychlorinated dibenzodioxin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Polychlorinated dibenzodioxin increases the expression of SLC22A4 [24]

Mycotoxins

  Aflatoxin B1

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Aflatoxin B1 increases the expression of SLC22A4 [17]

Acute Toxic Substance

  Cycloheximide

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Cycloheximide increases the expression of SLC22A4 [16]

  Formaldehyde

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Formaldehyde increases the expression of SLC22A4 [18]

  Cadmium

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Cadmium inhibits the activity of SLC22A4 [19]

  Thimerosal

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Thimerosal inhibits the activity of SLC22A4 [19]

Carcinogen

  Benzo(a)pyrene

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Benzo(a)pyrene increases the expression of SLC22A4 [25]

Health and Environmental Toxicant

  Perfluorooctane sulfonic acid

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Perfluorooctane sulfonic acid increases the expression of SLC22A4 [20]

  tris(1,3-dichloro-2-propyl)phosphate

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 tris(1,3-dichloro-2-propyl)phosphate increases the expression of SLC22A4 [21]
References
1 Probing the substrate specificity of the ergothioneine transporter with methimazole, hercynine, and organic cations. Biochem Pharmacol. 2007 Jul 15;74(2):309-16.
2 Novel membrane transporter OCTN1 mediates multispecific, bidirectional, and pH-dependent transport of organic cations. J Pharmacol Exp Ther. 1999 May;289(2):768-73.
3 Evaluation and prediction of potential drug-drug interactions of linagliptin using in vitro cell culture methods. Drug Metab Dispos. 2013 Jan;41(1):149-58.
4 Effects of ciglitazone and troglitazone on the proliferation of human stomach cancer cells. World J Gastroenterol. 2009 Jan 21;15(3):310-20.
5 Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
6 Differential gene expression in human hepatocyte cell lines exposed to the antiretroviral agent zidovudine. Arch Toxicol. 2014 Mar;88(3):609-23.
7 Interleukin-19 as a translational indicator of renal injury. Arch Toxicol. 2015 Jan;89(1):101-6.
8 Blood transcript immune signatures distinguish a subset of people with elevated serum ALT from others given acetaminophen. Clin Pharmacol Ther. 2016 Apr;99(4):432-41.
9 Multiple drug transporters mediate the placental transport of sulpiride. Arch Toxicol. 2017 Dec;91(12):3873-3884.
10 Endoplasmic reticulum stress and MAPK signaling pathway activation underlie leflunomide-induced toxicity in HepG2 Cells. Toxicology. 2017 Dec 1;392:11-21.
11 Bringing in vitro analysis closer to in vivo: Studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling. Toxicol Lett. 2018 Sep 15;294:184-192.
12 17 beta-Estradiol Activates HSF1 via MAPK Signaling in ER alpha-Positive Breast Cancer Cells. Cancers (Basel). 2019 Oct 11;11(10):1533.
13 Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
14 Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423.
15 Modulation of drug block of the cardiac potassium channel KCNA5 by the drug transporters OCTN1 and MDR1. Br J Pharmacol. 2010 Nov;161(5):1023-33.
16 Comparative analysis of AhR-mediated TCDD-elicited gene expression in human liver adult stem cells. Toxicol Sci. 2009 Nov;112(1):229-44.
17 Identification of early target genes of aflatoxin B1 in human hepatocytes, inter-individual variability and comparison with other genotoxic compounds. Toxicol Appl Pharmacol. 2012 Jan 15;258(2):176-87.
18 Characterization of formaldehyde's genotoxic mode of action by gene expression analysis in TK6 cells. Arch Toxicol. 2013 Nov;87(11):1999-2012.
19 Functional and molecular effects of mercury compounds on the human OCTN1 cation transporter: C50 and C136 are the targets for potent inhibition. Toxicol Sci. 2015 Mar;144(1):105-13.
20 Cord blood gene expression supports that prenatal exposure to perfluoroalkyl substances causes depressed immune functionality in early childhood. J Immunotoxicol. 2016;13(2):173-80.
21 Defensive and adverse energy-related molecular responses precede tris (1, 3-dichloro-2-propyl) phosphate cytotoxicity. J Appl Toxicol. 2016 May;36(5):649-58.
22 Transcriptional profiling of human bronchial epithelial cell BEAS-2B exposed to diesel and biomass ultrafine particles. BMC Genomics. 2018 Apr 27;19(1):302.
23 Comparison of transcriptome expression alterations by chronic exposure to low-dose bisphenol A in different subtypes of breast cancer cells. Toxicol Appl Pharmacol. 2019 Dec 15;385:114814.
24 The Ah receptor regulates growth factor expression in head and neck squamous cell carcinoma cell lines. Mol Carcinog. 2014 Oct;53(10):765-76.
25 Identification of a transcriptomic signature of food-relevant genotoxins in human HepaRG hepatocarcinoma cells. Food Chem Toxicol. 2020 Jun;140:111297.
26 Integration of transcriptome analysis with pathophysiological endpoints to evaluate cigarette smoke toxicity in an in vitro human airway tissue model. Arch Toxicol. 2021 May;95(5):1739-1761.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.